COVID-19 and Psoriasis: A Concise Systematic Review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | MedNEXT Journal of Medical and Health Sciences |
Texto Completo: | https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/60 |
Resumo: | Introduction: The effects on human health caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) lead to hyperinflammation processes, which can lead to meta-inflammation. This process can aggravate skin diseases, especially psoriasis. This is a chronic inflammatory skin disease associated with significant morbidity. This problem affects about 2-3% of people worldwide. Objective: to demonstrate, through a concise systematic review, the main considerations about the relationship between COVID-19 and psoriasis, showing the possible mechanisms for the worsening of this dermatological disease. Methods: The research was carried out from June 2021 to July 2021 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar, following the Systematic Review-PRISMA rules. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results: Psoriasis is a common chronic inflammatory skin disease and is autoimmune. Patients with COVID-19 may have features of hyper inflammation and even meta-inflammation. The triggering or exacerbating factor of psoriasis may be medications and, in addition, patients with COVID-19 may have psoriasis exacerbation. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease. It is envisioned that the use of azithromycin in cases of COVID 19 with pre-existing psoriasis can alleviate psoriatic lesions. Conclusion: The COVID 19 pandemic had a direct impact on dermatological diseases, especially psoriasis. Difficulty in accessing health care services and the stress load caused exacerbations in psoriasis cases. Studies recommend avoiding classic immunosuppressive agents such as methotrexate, cyclosporine, and TNF alpha inhibitors. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease. |
id |
FACERES-1_cf9fdc005be266c37440befa993f247c |
---|---|
oai_identifier_str |
oai:ojs2.mednext.zotarellifilhoscientificworks.com:article/60 |
network_acronym_str |
FACERES-1 |
network_name_str |
MedNEXT Journal of Medical and Health Sciences |
repository_id_str |
|
spelling |
COVID-19 and Psoriasis: A Concise Systematic ReviewCOVID-19SARS-CoV-2PsoriasisDermatological diseasesHyperinflammationMeta-inflammationIntroduction: The effects on human health caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) lead to hyperinflammation processes, which can lead to meta-inflammation. This process can aggravate skin diseases, especially psoriasis. This is a chronic inflammatory skin disease associated with significant morbidity. This problem affects about 2-3% of people worldwide. Objective: to demonstrate, through a concise systematic review, the main considerations about the relationship between COVID-19 and psoriasis, showing the possible mechanisms for the worsening of this dermatological disease. Methods: The research was carried out from June 2021 to July 2021 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar, following the Systematic Review-PRISMA rules. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results: Psoriasis is a common chronic inflammatory skin disease and is autoimmune. Patients with COVID-19 may have features of hyper inflammation and even meta-inflammation. The triggering or exacerbating factor of psoriasis may be medications and, in addition, patients with COVID-19 may have psoriasis exacerbation. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease. It is envisioned that the use of azithromycin in cases of COVID 19 with pre-existing psoriasis can alleviate psoriatic lesions. Conclusion: The COVID 19 pandemic had a direct impact on dermatological diseases, especially psoriasis. Difficulty in accessing health care services and the stress load caused exacerbations in psoriasis cases. Studies recommend avoiding classic immunosuppressive agents such as methotrexate, cyclosporine, and TNF alpha inhibitors. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease.Faceres2021-11-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticleapplication/pdfhttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/6010.54448/mdnt2143MedNEXT Journal of Medical and Health Sciences; Vol. 2 No. 4 (2021): MedNEXTMedNEXT Journal of Medical and Health Sciences; v. 2 n. 4 (2021): MedNEXT2763-567810.54448/mdnt214reponame:MedNEXT Journal of Medical and Health Sciencesinstname:Faculdade de Medicina em São José do Rio Preto (Faceres)instacron:FACERESenghttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/60/61Copyright (c) 2021 MedNEXT Journal of Medical and Health Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessRocha, Michelle SilvaAquino, Lorenna Lemos deRodrigues, Ágda Tamires da SilvaOliveira, Clarice Paiva deLazo, Lívia Mendes MontoyaSalviano, Juliana LeiteValadão, Letícia VieiraBatista, Marihana MirandaLopes, Vinícius BezerraRibas Filho, Durval2021-11-04T21:05:29Zoai:ojs2.mednext.zotarellifilhoscientificworks.com:article/60Revistahttps://mednext.zotarellifilhoscientificworks.com/index.php/mednextPUBhttps://mednext.zotarellifilhoscientificworks.com/index.php/mednext/oaimednextjmhs@zotarellifilhoscientificworks.com2763-56782763-5678opendoar:2021-11-04T21:05:29MedNEXT Journal of Medical and Health Sciences - Faculdade de Medicina em São José do Rio Preto (Faceres)false |
dc.title.none.fl_str_mv |
COVID-19 and Psoriasis: A Concise Systematic Review |
title |
COVID-19 and Psoriasis: A Concise Systematic Review |
spellingShingle |
COVID-19 and Psoriasis: A Concise Systematic Review Rocha, Michelle Silva COVID-19 SARS-CoV-2 Psoriasis Dermatological diseases Hyperinflammation Meta-inflammation |
title_short |
COVID-19 and Psoriasis: A Concise Systematic Review |
title_full |
COVID-19 and Psoriasis: A Concise Systematic Review |
title_fullStr |
COVID-19 and Psoriasis: A Concise Systematic Review |
title_full_unstemmed |
COVID-19 and Psoriasis: A Concise Systematic Review |
title_sort |
COVID-19 and Psoriasis: A Concise Systematic Review |
author |
Rocha, Michelle Silva |
author_facet |
Rocha, Michelle Silva Aquino, Lorenna Lemos de Rodrigues, Ágda Tamires da Silva Oliveira, Clarice Paiva de Lazo, Lívia Mendes Montoya Salviano, Juliana Leite Valadão, Letícia Vieira Batista, Marihana Miranda Lopes, Vinícius Bezerra Ribas Filho, Durval |
author_role |
author |
author2 |
Aquino, Lorenna Lemos de Rodrigues, Ágda Tamires da Silva Oliveira, Clarice Paiva de Lazo, Lívia Mendes Montoya Salviano, Juliana Leite Valadão, Letícia Vieira Batista, Marihana Miranda Lopes, Vinícius Bezerra Ribas Filho, Durval |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Rocha, Michelle Silva Aquino, Lorenna Lemos de Rodrigues, Ágda Tamires da Silva Oliveira, Clarice Paiva de Lazo, Lívia Mendes Montoya Salviano, Juliana Leite Valadão, Letícia Vieira Batista, Marihana Miranda Lopes, Vinícius Bezerra Ribas Filho, Durval |
dc.subject.por.fl_str_mv |
COVID-19 SARS-CoV-2 Psoriasis Dermatological diseases Hyperinflammation Meta-inflammation |
topic |
COVID-19 SARS-CoV-2 Psoriasis Dermatological diseases Hyperinflammation Meta-inflammation |
description |
Introduction: The effects on human health caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) lead to hyperinflammation processes, which can lead to meta-inflammation. This process can aggravate skin diseases, especially psoriasis. This is a chronic inflammatory skin disease associated with significant morbidity. This problem affects about 2-3% of people worldwide. Objective: to demonstrate, through a concise systematic review, the main considerations about the relationship between COVID-19 and psoriasis, showing the possible mechanisms for the worsening of this dermatological disease. Methods: The research was carried out from June 2021 to July 2021 and developed based on Scopus, PubMed, Science Direct, Scielo, and Google Scholar, following the Systematic Review-PRISMA rules. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results: Psoriasis is a common chronic inflammatory skin disease and is autoimmune. Patients with COVID-19 may have features of hyper inflammation and even meta-inflammation. The triggering or exacerbating factor of psoriasis may be medications and, in addition, patients with COVID-19 may have psoriasis exacerbation. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease. It is envisioned that the use of azithromycin in cases of COVID 19 with pre-existing psoriasis can alleviate psoriatic lesions. Conclusion: The COVID 19 pandemic had a direct impact on dermatological diseases, especially psoriasis. Difficulty in accessing health care services and the stress load caused exacerbations in psoriasis cases. Studies recommend avoiding classic immunosuppressive agents such as methotrexate, cyclosporine, and TNF alpha inhibitors. Reports indicated that psoriasis patients using biological products were no longer susceptible to COVID-19 and the severe clinical course of the disease. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-11-04 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/60 10.54448/mdnt2143 |
url |
https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/60 |
identifier_str_mv |
10.54448/mdnt2143 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://mednext.zotarellifilhoscientificworks.com/index.php/mednext/article/view/60/61 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2021 MedNEXT Journal of Medical and Health Sciences https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2021 MedNEXT Journal of Medical and Health Sciences https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Faceres |
publisher.none.fl_str_mv |
Faceres |
dc.source.none.fl_str_mv |
MedNEXT Journal of Medical and Health Sciences; Vol. 2 No. 4 (2021): MedNEXT MedNEXT Journal of Medical and Health Sciences; v. 2 n. 4 (2021): MedNEXT 2763-5678 10.54448/mdnt214 reponame:MedNEXT Journal of Medical and Health Sciences instname:Faculdade de Medicina em São José do Rio Preto (Faceres) instacron:FACERES |
instname_str |
Faculdade de Medicina em São José do Rio Preto (Faceres) |
instacron_str |
FACERES |
institution |
FACERES |
reponame_str |
MedNEXT Journal of Medical and Health Sciences |
collection |
MedNEXT Journal of Medical and Health Sciences |
repository.name.fl_str_mv |
MedNEXT Journal of Medical and Health Sciences - Faculdade de Medicina em São José do Rio Preto (Faceres) |
repository.mail.fl_str_mv |
mednextjmhs@zotarellifilhoscientificworks.com |
_version_ |
1796798219171135488 |